Pneomococcal Vaccine Clinical Trials Pneomococcal Vaccine RSS feedThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Extension Safety and Immunogenicity Study of GPNV-001
Condition:   Pneumococcal Infections Interventions:   Biological: Gamma-PN3;   Biological: Pneumovax-23;   Biological: Prevenar-13;   Biological: Placebo Sponsor:   GPN Vaccines Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 8, 2023 Category: Research Source Type: clinical trials

Merck Announces V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Met Key Immunogenicity and Safety Endpoints in Two Phase 3 Trials
RAHWAY, N.J.--(BUSINESS WIRE) July 27, 2023 -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from two Phase 3 trials evaluating V116, the company’s investigational 21-valent... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - July 27, 2023 Category: Pharmaceuticals Source Type: clinical trials

Consistency, Immunogenicity, and Safety of Three Batches of 15-valent Pneumococcal Conjugate Vaccine
Condition:   Healthy Volunteers Interventions:   Biological: 15-valent pneumococcal conjugate vaccine 202210001;   Biological: 15-valent pneumococcal conjugate vaccineY202210002;   Biological: 15-valent pneumococcal conjugate vaccineY202210003;   Biological: 15-valent pneumococcal conjugate vaccineY202210004;   Biological: 13 valent pneumo coccal polysaccharide conjugate vaccine Sponsor:   Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 11, 2023 Category: Research Source Type: clinical trials